Kallikreins

• 

  Subject Areas on Research

  • A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. 
  • American Society of Clinical Oncology 2013 top five list in oncology. 
  • Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass. 
  • Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate. 
  • Characterization of inactive renin from human kidney and plasma. Evidence of a renal source of circulating inactive renin. 
  • Characterization of prorenin activation using a synthetic peptide substrate. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 
  • Decreased kallikrein excretion in renal transplant treated with cyclosporine A. 
  • Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men. 
  • Disseminated intravascular coagulation: a reappraisal. 
  • Emerging applications of aptamers for anticoagulation and hemostasis. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. 
  • Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. 
  • Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system. 
  • Kallikrein-related mRNAs of the rat submaxillary gland: nucleotide sequences of four distinct types including tonin. 
  • Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey. 
  • Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system. 
  • Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. 
  • Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. 
  • Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. 
  • Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. 
  • Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. 
  • Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men. 
  • Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. 
  • Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. 
  • Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer. 
  • Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment? 
  • Rat pancreatic kallikrein mRNA: nucleotide sequence and amino acid sequence of the encoded preproenzyme. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 
  • Surveillance after prostate focal therapy. 
  • Synergistic and tunable human gene activation by combinations of synthetic transcription factors. 
  • TET2 binds the androgen receptor and loss is associated with prostate cancer. 
  • The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins. 
  • The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. 
  • The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. 
  • Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. 
  • Tissue-specific expression of kallikrein-related genes in the rat. 
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 
  • Tubular markers in renal transplant patients under cyclosporine. 
  • Urinary kallikrein in dogs with constriction of one renal artery. 
• 

  Keywords of People

  • Nielsen, Karen Cristina, Associate Professor of Anesthesiology, Anesthesiology, Ambulatory